Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (6246)
All Articles published online
|
Publishing Process of This Article
|
Apr 16, 2022 (publication date) through Dec 19, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Cases
ISSN
2307-8960
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| Yuan F, Liu N, Yang MZ, Zhang XT, Luo H, Zhou H. Circulating tumor DNA genomic profiling reveals the complicated olaparib-resistance mechanism in prostate cancer salvage therapy: A case report. World J Clin Cases 2022; 10(11): 3461-3471 [PMID: 35611209 DOI: 10.12998/wjcc.v10.i11.3461] |
|
|
|
| ©2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA | |
| For: | Yuan F, Liu N, Yang MZ, Zhang XT, Luo H, Zhou H. Circulating tumor DNA genomic profiling reveals the complicated olaparib-resistance mechanism in prostate cancer salvage therapy: A case report. World J Clin Cases 2022; 10(11): 3461-3471 [PMID: 35611209 DOI: 10.12998/wjcc.v10.i11.3461] |
|---|---|
| URL: | https://www.wjgnet.com/2307-8960/full/v10/i11/3461.htm |
| Number | Citing Articles |
| 1 |
|
| 2 |
Marta Lopez-Valcarcel. Liquid biopsy to personalize treatment for metastatic prostate cancer. American Journal of Translational Research 2024; 16(5): 1531 doi: 10.62347/DICU9510
|
| 3 |
Amr Ali Mohamed Abdelgawwad El-Sehrawy, Mahmood Yaseen Mukhlif, Aysar Ashour Khalaf, Subasini Uthirapathy, Suhas Ballal, Abhayveer Singh, V. Kavitha, Laxmidhar Maharana, Hayder Ridha-Salman, Ahmed Remthan Hussein Al-Altememe. Breaking barriers: Deciphering the mechanisms of Olaparib resistance in prostate cancer. Seminars in Oncology 2025; 52(4): 152375 doi: 10.1016/j.seminoncol.2025.152375
|
| 4 |
Wei He, Yutian Xiao, Shi Yan, Yasheng Zhu, Shancheng Ren. Cell-free DNA in the management of prostate cancer: Current status and future prospective. Asian Journal of Urology 2023; 10(3): 298 doi: 10.1016/j.ajur.2022.11.002
|
| 5 |
Nouhaila Chanhih, Abdelilah Laraqui, Salma Hassine, Ahmed Ameur, Larbi Hamedoun, Hicham El Annaz, Rachid Abi, Mohamed Rida Tagajdid, Idriss Lahlou Amine, Khalid Ennibi, Abdelaziz Benjouad, Lamiae Belayachi. Circulating Tumor DNA as a Biomarker for Precision Medicine in Prostate Cancer: A Systematic Review. International Journal of Molecular Sciences 2025; 26(22): 11049 doi: 10.3390/ijms262211049
|
| 6 |
Maako Kawamura, Hiroshi Tada, Hidekazu Shirota, Miki Dobashi, Noriko Takenaga, Hiroyuki Yasojima, Narumi Harada‐shoji, Keigo Komine, Kenichi Nakamura, Minoru Miyashita, Hisato Kawakami. Emergence of PALB2 Reversion Mutations as a Mechanism of Resistance to Niraparib in Breast Cancer: A Case Report. Cancer Science 2025; 116(12): 3540 doi: 10.1111/cas.70210
|